 25829-04      10 May 2018 3:41 PM   Proof Nine
Group at a glance
A BALANCED PORTFOLIO WITH A STRONG RECORD OF GROWTH
IP Group partners with leading research institutions in countries where leading 
research is produced. The Group has three areas of geographic focus; the UK, the 
US and our recently formed business in Australasia. In total, the Group has access 
to R&D emanating from 32 universities or research institutions around the world 
comprising 18 in the UK, 5 in the US and 9 in Australia/New Zealand. IP Group has 
access to commercialisable intellectual property from universities whose academic 
staff have published 16.8% of the world’s Top Research. The Directors therefore 
believe the Group is the international market leader in the emerging university IP 
commercialisation sector.
Technology
82 
Life 
Sciences
704.4 
Life 
Sciences
73 
Technology
334.0 
Multiple Sectors 
62.9 
Multiple Sectors 
3 
UNPARALLELED ACCESS TO GLOBAL RESEARCH HUBS
UK THE GOLDEN TRIANGLE
America THE AMTRAK CORRIDOR
Australasia THE GO9 UNIVERSITIES
 
 y University of Adelaide
 y Australian National 
University
 y The University of 
Melbourne
 y Monash University
 y UNSW Sydney
 y The University of 
Queensland
 y The University of 
Sydney
 y The University of 
Western Australia
 y The University of 
Auckland
  READ ABOUT OUR PARTNERS IN OUR BUSINESS MODEL  
ON PAGES 14 TO 15
25.8 26.3 26.7 28.4 31.5
38.7
44.5
51.1 55.5
274.1
Xeros Technology Group (Q)
Cell Medica (P)
Circassia (Q)
Actual Experience (Q)
Ceres Power Holdings (Q)
Diurnal Group (Q)
PsiOxus Therapeutics (P)
Istesso (P)
Oxford Sciences Innovation (P)
Oxford Nanopore (P)
TOP 10
as at 
31 December
2017
Technology 
Life Sciences 
Multiple Sectors 
Top 10 holdings by value
(£m)
2016 2015 2014
451.3
2013
706.5
2017
1,326.2
714.3
315.5
125.4pps
125pps 127pps
94pps
84pps
IP Group Hard NAV
(£m)
By fair value*
(£m)
By number of companies*
*  Excludes de minimis & organic holdings
IP Group plc Annual Report and Accounts for the year ended 31 December 2017 4 25829-04      10 May 2018 3:41 PM   Proof Nine
AN ENLARGED GLOBAL BUSINESS
IP Group’s vision is to create an international leader in IP commercialisation with  
an enlarged platform for growth and investment. The combination with Touchstone 
provides the Group with critical mass, a better-balanced portfolio across two  
main sectors as well as additional partnerships including Imperial College London 
where the business also operates the ‘technology transfer operation’ known as 
‘Imperial Innovations’.
Technology TOTAL
STAGE
Value of 
companies in 
the portfolio
2017 net 
portfolio gains
Number of 
portfolio 
companies
Focus
Development
Early stage
Life Sciences
£1,038.4m
1
£94.2m
2
155
12 7 19
40 44 84
21 31 52
£704.4m £334.0m
£63.2m £30.5m
73 82
1
 Excludes £69.9m related to multi-sector platforms, de minimis and organic portfolio holdings. See page 27 for further details
2
 Includes £0.5m gains relating to multi-sector platforms’
Stock Code: IPO   www.ipgroupplc.com
5
Strategic Report Business Overview 25829-04      10 May 2018 3:41 PM   Proof Nine
IP Group plc Annual Report and Accounts for the year ended 31 December 2017 6
Create
To build and maintain a pipeline  
of compelling intellectual  
property-based opportunities 25829-04      10 May 2018 3:41 PM   Proof Nine
Our business & strategy 
Chairman’s summary 8
Market 11
Business model 14
Our strategy 16
Our performance 
Key performance indicators 18
Operational review 20
Portfolio review 23
Financial review 40
Risk management 46
Our business ethics and  
social responsibility 54
STRATEGIC REPORT
Stock Code: IPO www.ipgroupplc.com
7
